{'52WeekChange': 2.7934458,
 'SandP52WeekChange': None,
 'address1': 'Health Discovery Building',
 'address2': '1601 Trinity Street Building B, Dell Medical Center Suite 3.322',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.5,
 'askSize': 4000,
 'averageDailyVolume10Day': 3307562,
 'averageVolume': 2805768,
 'averageVolume10days': 3307562,
 'beta': -1.009094,
 'beta3Year': None,
 'bid': 3.45,
 'bidSize': 900,
 'bookValue': 0.729,
 'category': None,
 'circulatingSupply': None,
 'city': 'Austin',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.7899,
 'dayLow': 3.467,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.975,
 'enterpriseToRevenue': None,
 'enterpriseValue': 98154776,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.1684287,
 'fiftyTwoWeekHigh': 7.03,
 'fiftyTwoWeekLow': 0.231,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 26778010,
 'forwardEps': 0.25,
 'forwardPE': 14.76,
 'fromCurrency': None,
 'fullTimeEmployees': 8,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.22997999,
 'heldPercentInstitutions': 0.12815,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/genprex.com',
 'longBusinessSummary': 'Genprex, Inc. operates as a clinical-stage gene '
                        'therapy company. The company engages in developing '
                        'technologies for cancer patients based upon a '
                        'proprietary technology platform. Its platform '
                        'technologies are designed to administer '
                        'cancer-fighting genes by encapsulating them into '
                        'nanoscale hollow spheres called nanovesicles, which '
                        'are then administered intravenously and taken up by '
                        'tumor cells where they express proteins that are '
                        "missing or found in low quantities. The company's "
                        'lead product candidate, Oncoprex immunogene therapy '
                        'for non-small cell lung cancer (NSCLC), has a '
                        'multimodal mechanism of action whereby it interrupts '
                        'cell signaling pathways that cause replication and '
                        'proliferation of cancer cells, re-establishes '
                        'pathways for apoptosis, or programmed cell death, in '
                        'cancer cells, and modulates the immune response '
                        'against cancer cells. Oncoprex also block mechanisms '
                        'that create drug resistance. The company was founded '
                        'in 2009 and is headquartered in Austin, Texas.',
 'longName': 'Genprex, Inc.',
 'market': 'us_market',
 'marketCap': 142541744,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_225557674',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -14062142,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.63,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '877-774-4679',
 'previousClose': 3.82,
 'priceHint': 4,
 'priceToBook': 5.0617285,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.7899,
 'regularMarketDayLow': 3.467,
 'regularMarketOpen': 3.63,
 'regularMarketPreviousClose': 3.82,
 'regularMarketPrice': 3.63,
 'regularMarketVolume': 1443718,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 38629200,
 'sharesPercentSharesOut': 0.1047,
 'sharesShort': 4042699,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3037753,
 'shortName': 'Genprex, Inc.',
 'shortPercentOfFloat': 0.1184,
 'shortRatio': 1.79,
 'startDate': None,
 'state': 'TX',
 'strikePrice': None,
 'symbol': 'GNPX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.733,
 'twoHundredDayAverage': 2.6911583,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'd506e914-dc7c-30af-b5b9-638e83c34981',
 'volume': 1443718,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.genprex.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '78712'}